^
    Back
    Association details:
    Biomarker:RPTOR mutation
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

    Published date:
    12/10/2023
    Excerpt:
    RPTOR-Mut melanoma patients exhibited a higher objective response rate (ORR) than RPTOR-WT patients in the discovery cohort (55.0% vs. 29.0%, P = 0.022). RPTOR-Mut patients exhibited higher TMB than RPTOR-WT patients in both discovery and validation cohorts (P < 0.001). RPTOR-Mut melanoma patients had an increased number of DNA damage response (DDR) mutations in TCGA-SKCM cohort....Our results suggest that RPTOR mutation could serve as a predictor of effective immunotherapy for melanoma.
    DOI:
    10.1007/s10637-023-01413-z
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.

    Published date:
    05/25/2023
    Excerpt:
    In discovery cohort, compared to RPTOR-wildtype patients, the RPTOR-mutant patients achieved prolonged OS (median OS: not reach, NR vs 22.7 months, HR (95%CI): 0.47(0.22-0.99), P = 0.043)…. Survival analysis shows RPTOR mutation have a good link with longer OS after immunotherapy.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9524